Results 91 to 100 of about 1,177,456 (242)

Plasma Proteome Reflects Tissue Damage and Clinical Manifestations in Patients With Inflammatory Myopathies

Arthritis &Rheumatology, EarlyView.
Objective Tissue‐specific biomarkers that are reliable and associated with clinical manifestations of idiopathic inflammatory myopathy (IIM) are lacking. The blood circulation in individuals serves as a central conduit, allowing communication between tissues and facilitating clearance and recycling of tissue‐derived proteins.
Yue‐Bei Luo, Josefin Kenrick, Angeles S. Galindo‐Feria, Antonella Notarnicola, Ana Daniela Ulloa Navas, Irene Peralta‐Garcia, Orane Demuynck, Andrea Kemp, Valérie Leclair, Karin Lodin, Eveline Van Gompel, Lara Dani, Fabricio Espinosa‐Ortega, Maryam Dastmalchi, Leonid Padyukov, Charlotta Preger, María Bueno Álvez, Mathias Uhlén, Peter Nilsson, Fredrik Edfors, Lina‐Marcela Diaz‐Gallo, Elisa Pin, Ingrid E. Lundberg, Begum Horuluoglu   +23 more
wiley   +1 more source

The synergistic impact of granulocytic myeloid‐derived suppressor cells and innate lymphoid cells in systemic sclerosis

Arthritis &Rheumatology, Accepted Article.
Objective Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by immune dysregulation and fibrosis, with myeloid‐derived suppressor cells (MDSCs) emerging as important regulators of immune responses. However, the role of MDSCs in SSc‐associated fibrosis and their interactions with other immune cell populations remain poorly ...
Stefanie Weber, Mario R. Angeli, Hashem Mohammadian, Hannah Labinsky, Maria Gabriella Raimondo, Richard Demmler, Yuko Ariza, Thomas Wohlfahrt, Markus Luber, Yi‐Nan Li, Jörg H.W. Distler, Tobias Bäuerle, Georg Schett, Simon Rauber, Andreas Ramming, Alina M. Ramming   +15 more
wiley   +1 more source

Initial treatment strategies and outcomes across haemodynamic thresholds and risk stratification in incident systemic sclerosis–associated pulmonary arterial hypertension: a EUSTAR analysis

Arthritis &Rheumatology, Accepted Article.
Objective Real‐world initial treatment strategies in SSc‐PAH remain incompletely described. We aimed to characterise these strategies across haemodynamic thresholds and risk strata and evaluate outcome associations. Methods We analysed treatment‐naïve SSc‐PAH patients in EUSTAR (2000–2021) fulfilling the 2022 haemodynamic definition.
Hilde Jenssen Bjørkekjær, Cosimo Bruni, Kaspar Broch, Cathrine Brunborg, Patricia E Carreira, Paolo Airò, Carmen Pilar Simeón‐Aznar, Marie‐Elise Truchetet, Alessandro Giollo, Alexandra Balbir‐Gurman, Mickael Martin, Christopher P Denton, Armando Gabrielli, Francesco Del Galdo, Madelon C. Vonk, Håvard Fretheim, Helle Bitter, Øyvind Midtvedt, Arne K. Andreassen, Sverre Høie, Yoshiya Tanaka, Gabriela Riemekasten, Ulf Müller‐Ladner, Marco Matucci‐Cerinic, Ivan Castellví, Elise Siegert, Eric Hachulla, Øyvind Molberg, Oliver Distler, Anna‐Maria Hoffmann‐Vold, on behalf of the EUSTAR collaborators   +30 more
wiley   +1 more source

State of the Art in Idiopathic Pulmonary Fibrosis

, 2022
Idiopathic pulmonary fibrosis (IPF) is a form of usual interstitial pneumonia (UIP), though its origin is unknown [...
Malgorzata Wygrecka, Elie El Agha, Wygrecka, Malgorzata, El Agha, Elie   +3 more
core   +1 more source

Synovial Tissue‐Guided Interleukin‐17A Inhibition for Refractory Arthritis in a Patient With Systemic Juvenile Idiopathic Arthritis

Arthritis &Rheumatology, Accepted Article.
Objective The objective of this study was to characterize the clinical, immunologic, and synovial tissue features of a patient with a systemic juvenile idiopathic arthritis (sJIA) who carries a novel heterozygous STAT5B loss‐of‐function variant (p.Gln139Ter) and whose arthritis responded markedly to interleukin‐17A (IL‐17A) inhibition.
Indira Sriram, Tomohiro Kawabe, Hitoshi Irabu, Mariana Correia Marques, Clara Lin, Alisa Gaskell, Jun Inamo, Michael R. Clay, Roselyn Fierkens, Robert C. Fuhlbrigge, Jeremy D. Prager, Norman R. Friedman, Sarah A. Gitomer, Michael J. Ombrello, Kentaro Yomogida   +14 more
wiley   +1 more source

Managing comorbidities in idiopathic pulmonary fibrosis

, 2015
Blair G Fulton,1 Christopher J Ryerson1,2 1Department of Medicine, 2Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada Abstract: Major risk factors for idiopathic pulmonary fibrosis (IPF) include older age and a ...
Fulton BG, Ryerson CJ
core  

Repeated intradermal lipopolysaccharide challenge responses in healthy volunteers: Implications for clinical pharmacology studies

British Journal of Clinical Pharmacology, EarlyView.
Aim Intradermal application of lipopolysaccharide (LPS), a Toll‐like receptor 4 agonist, induces a local inflammatory response and is used as a human challenge model to evaluate the pharmacodynamics of investigational medicinal products. While currently applied in a single, parallel‐group setting, alternative within‐subject designs involving repeated ...
Alexandra A. J. Sillé, Juliette A. van den Noort, Iva Lelios, Diana R. Pereira, Marzia A. Scelsi, Erica S. Klaassen, Philipp Schoenenberger, Naomi B. Klarenbeek, Pierre‐Eric Juif, Pascal Espie, Manon A. A. Jansen, Matthijs Moerland, Richard W. D. Welford   +12 more
wiley   +1 more source

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

BMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim, Marwa Ahmed El‐Naka, Wedad M. Nageeb, Atta Ullah Khan, Noura M. Seleem, Aliaa Abdelghafar, Doaa Zamel, Yang Liu, Qigai He, Wentao Li   +9 more
wiley   +1 more source

Obstacles to early treatment of idiopathic pulmonary fibrosis: current perspectives

, 2019
Teng Moua, Jay H Ryu Department of Medicine, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester MN, USA Abstract: Idiopathic pulmonary fibrosis is a progressive and fatal fibrotic lung disease which has seen new opportunity ...
Moua T, Ryu JH
core  

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source